Compare Enveric Biosciences Inc (ENVB) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs ProShares Ultra Gold ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while ProShares Ultra Gold ETF trades at $46.26 (market cap $715.43M). The key difference: ProShares Ultra Gold ETF is far larger — about 106.9× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (41,141 versus 3,002,043). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and ProShares Ultra Gold ETF for 23 Days on average.
| ENVB | UGL | |
|---|---|---|
Market Cap | $6.69M | $715.43M |
Volume | 41,141 | 3,002,043 |
Sector | Health | Leveraged / Inverse |
52-Week High | $10.80 | $85.62 |
52-Week Low | $1.27 | $42.79 |
Typical Hold Time | 14 Days | 23 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
UGL stock is trading at $44.43, down 3.29% over the past day amid a broader bearish technical signal. The stock faces selling pressure with moving averages and oscillators indicating a downtrend, while key support lies at $43. Recent news highlights gold's volatility driven by shifting Federal Reserve rate expectations and Treasury yield movements, impacting sentiment.
The outlook remains cautious with technical indicators signaling bearish momentum, though oversold conditions on the 12-day RSI may offer short-term relief. Risks include persistent macroeconomic headwinds from interest rates and dollar strength, while the lack of available fundamental data limits visibility on the company's financial health and valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
